Ophthalmic phototherapy device and associated treatment method

• US 9,782,604 B2
• Filed: 03/25/2016
• Issued: 10/10/2017
• Est. Priority Date: 04/14/2005
• Status: Active Grant

• Current Assignee: Photospectra Health Sciences, Inc.
• Original Assignee: Photospectra Health Sciences, Inc.
• Inventors: Dotson, Robert S, Merry, Graham
• Primary Examiner(s): Thomson, William
• Assistant Examiner(s): Downey, John R.
• Application Number:
  US15/081,805
• Publication Number:
  US 20160206897A1
• Time in Patent Office: 564 Days
• Field of Search: 606 4- 6
• CPC Class Codes: A61B 3/102 for optical coherence tomography [OCT]
• CPC Class Codes: A61B 3/12 for looking at the eye fundus, e.g. ophthalmoscopes A61B3/13 takes precedence
• CPC Class Codes: A61B 3/1241 specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
• CPC Class Codes: A61B 3/14 Arrangements specially adapted for eye photography apparatus or arrangements for taking photographs per se G03B
• CPC Class Codes: A61F 2009/00868 Ciliary muscles or trabecular meshwork
• CPC Class Codes: A61F 2009/00872 Cornea
• CPC Class Codes: A61F 2009/00891 Glaucoma
• CPC Class Codes: A61F 9/0079 using non-laser electromagnetic radiation, e.g. non-coherent light or microwaves
• CPC Class Codes: A61N 2005/0626 Monitoring, verifying, controlling systems and methods
• CPC Class Codes: A61N 2005/0644 Handheld applicators
• CPC Class Codes: A61N 2005/0652 Arrays of diodes
• CPC Class Codes: A61N 2005/0659 infrared
• CPC Class Codes: A61N 2005/0663 Coloured light
• CPC Class Codes: A61N 5/0613 Apparatus adapted for a specific treatment
• CPC Class Codes: A61N 5/067 using laser light

Abstract

An ophthalmic phototherapy device and associated phototherapy treatment method for promoting healing of damaged or diseased eye tissue. The ophthalmic phototherapy device includes a light emitting mechanism for transmitting light of at least one preselected wavelength to the eye tissue. The ophthalmic phototherapy method includes directing light of at least one wavelength for a selected period of time to a portion of damaged or diseased eye tissue, whereby the light transmitted to the damaged or diseased eye tissue stimulates cellular activity in the eye tissue to promote healing.

Claims

1. A method for promoting recovery of retinal tissue in an eye of a patient exhibiting dry age-related macular degeneration, said method comprising:

delivering two or more light dosages of different wavelengths onto retinal tissue in an eye of a patient exhibiting dry age-related macular degeneration;

wherein each of said two or more light dosages is of at least 10<sup>−

2</sup> J/cm²,

wherein a first light dosage of said two or more light dosages has a first wavelength of visible light between approximately 577 nm and 597 nm and a second light dosage of said two or more light dosages has a second wavelength of visible light between approximately 640 nm and 700 nm,

wherein each of said two or more light dosages is of sufficient energy density to modulate one or more cellular activities in said retinal tissue and to promote the recovery of said retinal tissue.

2. The method of claim 1 wherein at least one of said two or more light dosages is delivered to said retinal tissue via a continuous beam of light and at least another of said two or more light dosages is delivered to said retinal tissue via a pulsing beam of light.

3. The method of claim 1, further comprising:

delivering a third light dosage of a third wavelength onto said retinal tissue,

wherein said third wavelength is different than the first and second wavelengths and

wherein said third light dosage is of a sufficient energy density to modulate one or more cellular activities in said retinal tissue and to promote the recovery of said retinal tissue.

4. The method of claim 3 wherein said third wavelength is between 490 and 810 nm.

5. The method of claim 3 wherein said third wavelength is between 490 and 950 nm.

6. The method of claim 3 wherein said third wavelength is between 850 and 950 nm.

7. The method of claim 1 wherein said first wavelength is approximately 590 nm.

8. The method of claim 1 wherein said second wavelength is approximately 670 nm.

9. The method of claim 3 wherein said third wavelength is approximately 850 nm.

10. The method of claim 3 wherein said first wavelength is approximately 590 nm, said second wavelength is approximately 670 nm, and said third wavelength is approximately 850 nm.

11. The method of claim 3 wherein said second wavelength is approximately 670 nm and said third wavelength is approximately 850 nm.

12. The method of claim 3 wherein said first light dosage modulates a first cellular activity in said retinal tissue, said second light dosage modulates a second cellular activity in said retinal tissue, and said third light dosage modulates a third cellular activity in said retinal tissue.

13. The method of claim 1 wherein each of said two or more light dosages is delivered to said retinal tissue while an eyelid of the eye of the patient remains open.

14. A method for promoting the recovery of retinal tissue in an eye of a patient exhibiting dry age-related macular degeneration, said method comprising:

directing onto said retinal tissue a continuous beam of light comprising visible light having a first wavelength,

wherein said continuous beam of light is delivered for a first duration such that said continuous beam of light delivers a first dosage of at least 10<sup>−

2</sup> Joules/cm² to said retinal tissue and

directing onto said retinal tissue a pulsing beam of light comprising light having a second wavelength,

wherein said pulsing beam of light is delivered for a second duration such that said pulsing beam of light delivers a second dosage of at least 10<sup>−

2</sup> Joules/cm² to said retinal tissue and

wherein each of said first and second light beams is of sufficient energy density to modulate one or more cellular activities in said retinal tissue and to promote the recovery of said retinal tissue.

15. The method of claim 14 wherein one of said continuous and pulsing light beams has a wavelength of visible light between 577 nm and 597 nm and the other of said continuous and pulsing light beams has a wavelength of visible light between 640 nm and 700 nm.

16. The method of claim 14, further comprising:

directing onto said retinal tissue a third beam of light comprising light having a third wavelength,

wherein said third wavelength is different than said first and second wavelengths and

wherein said third beam of light is of a sufficient energy density to modulate one or more cellular activities in said retinal tissue and to promote the recovery of said retinal tissue.

17. The method of claim 16 wherein said third wavelength is between 490 nm and 810 nm.

18. The method of claim 16 wherein the third wavelength is between 850 nm and 950 nm.

19. The method of claim 14 wherein each of said continuous and pulsing light beams is delivered to said retinal tissue while an eyelid of the eye of the patient remains open.

20. The method of claim 16 wherein said first wavelength is approximately 590 nm, said second wavelength is approximately 670 nm, and said third wavelength is approximately 850 nm.